IP vs PACB: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
IP is the larger of the two ($18.43B market cap): the incumbent the market prices for continued execution (12.66x forward earnings, beta 0.94). PACB is the smaller challenger ($691.60M), priced similarly on forward earnings (-5.33x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
IP vs PACB: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IP | PACB | What it tells you |
|---|---|---|---|
| Market cap | $18.43B | $691.60M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 12.66 | -5.33 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.94 | 2.20 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 26% of range | 49% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how IP and PACB affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IP and PACB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IP and PACB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does International Paper (IP) do?
International Paper is a leading global producer of fiber-based packaging, pulp, and related products, best known for corrugated containers and the containerboard that goes into them. Its boxes carry everything from food and beverages to e-commerce shipments and industrial goods, so demand broadly tracks consumer and industrial activity. The company sells mainly to businesses rather than consumers, and its economics turn on containerboard pricing, box volumes, input costs like fiber and energy, and mill utilization. As a large, capital-intensive manufacturer, it competes on cost, scale, and its distribution and converting network.
What does Pacific Biosciences of California (PACB) do?
Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. Its high-throughput Revio system serves production genomics labs generating reference-quality genomes, while the newer benchtop Vega, a smaller and much cheaper instrument, aims to put HiFi long reads on more lab benches and introduce new users to the platform. Like most sequencing companies, PacBio runs a razor-and-blade model: it sells instruments, then earns recurring, higher-margin revenue from the consumables and reagents customers buy to run them. Over the trailing twelve months through June 2026 revenue was about $159 million, roughly 2% lower year over year, with quarterly sales stuck in a $37 million to $45 million band.
IP vs PACB: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- IP drivers: DS Smith integration and global scale; Cost cuts and footprint optimization.
- PACB drivers: HiFi long-read differentiation; Vega benchtop and installed-base growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The main risk is cyclicality: box volumes and containerboard pricing move with consumer and industrial activity, so an economic slowdown can reduce demand and pressure pricing and margins, as recent low-single-digit volume softness showed. For PACB, the dominant risk is that PacBio is unprofitable and burning cash: it lost about $131 million over the trailing twelve months, used roughly $118 million in operating cash, and carries about $709 million of debt against roughly $237 million of cash, so it depends on reaching breakeven before that cushion is stressed.
IP or PACB: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IP if you believe its drivers more; PACB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IP and PACB guides.
IP vs PACB: the full fundamentals
IP. Figures are approximate and tied to the asOf date; verify live numbers before acting. With trailing GAAP results distorted by charges, International Paper is valued on cash flow and recovery estimates: about 0.75 times sales, roughly 7 times EBITDA and about 11 times 2027 consensus EPS, with a dividend yield near 5.4% that reflects both the low share price and investor doubt. The outcome for the EMEA business (sale price or spin-off) and the October 28, 2026 third-quarter report, where consensus looks for EPS of about $0.28 on $6.26 billion of revenue, matter more to the thesis than a single point-in-time multiple.
PACB. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because PacBio is unprofitable, P/E does not apply, and at about 3.5 times trailing sales the stock is valued on whether revenue can grow again (consensus looks for about 19% growth in 2027) and how fast losses shrink relative to a cash balance that is smaller than its debt. Instrument placements, consumables pull-through and the November 4 report matter far more than any single accounting figure, which keeps the stock volatile.
Headline figures (approximate, October 2026): IP shows revenue (ttm) ~$24.2 billion; Q2 2026 ~$6.0 billion, down ~2% year over year, net income (ttm) ~-$2.7 billion on restructuring and impairment charges; Q2 2026 EPS $0.04 vs -$0.04 estimate, margins (ttm) Gross ~30%; operating ~2%, p/e No trailing P/E (loss); ~11x 2027 consensus EPS of ~$3.05; PACB shows revenue (ttm) ~$159 million, down ~2% year over year, latest quarter (q2 2026) Revenue ~$39.0 million; loss $0.14 per share vs ~$0.13 expected, net income (ttm) Loss of ~$131 million; trailing EPS ~-$0.43, gross margin (ttm) ~29%; operating margin deeply negative.
The bottom line: IP vs PACB
IP and PACB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IP and PACB exposure against your real portfolio. It is not an investment adviser.
Wondering how IP or PACB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about International Paper
Ask Walnut's AI anything about IP and see how it fits what you own.
FAQ
What is the difference between IP and PACB?
+
International Paper is a leading global producer of fiber-based packaging, pulp, and related products, best known for corrugated containers and the containerboard that goes into them. Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IP or PACB the better stock?
+
Neither is universally better. IP is the larger incumbent; PACB is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IP or PACB?
+
On forward P/E (as of November 2026), IP trades at 12.66x and PACB at -5.33x, so PACB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IP and PACB?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IP vs PACB?
+
IP: The main risk is cyclicality: box volumes and containerboard pricing move with consumer and industrial activity, so an economic slowdown can reduce demand and pressure pricing and margins, as recent low-single-digit volume softness showed. The transformation adds substantial execution risk: integrating DS Smith, capturing synergies, and separating into two companies all carry costs, distraction, and the possibility of dis-synergies or delays. Heavy restructuring and impairment charges produced a trailing net loss of about $2.7 billion and continue to weigh on 2026 earnings even as they set up future savings. The dividend, at $1.85 a share and a yield near 5.4%, is far above trailing GAAP earnings, so its coverage depends on cash flow (about $1.65 billion of trailing free cash flow) and on the earnings recovery analysts expect. A sale of the European business at a discount to its purchase price would lock in value destruction from the DS Smith deal. Input costs for fiber, energy, and chemicals are volatile and can compress margins. The business is capital intensive and carries debt increased by the DS Smith deal, so higher rates raise financing costs. Trade policy, tariffs, and currency swings add further uncertainty across its now larger international footprint. PACB: The dominant risk is that PacBio is unprofitable and burning cash: it lost about $131 million over the trailing twelve months, used roughly $118 million in operating cash, and carries about $709 million of debt against roughly $237 million of cash, so it depends on reaching breakeven before that cushion is stressed. Growth has stalled, with trailing revenue down about 2% and full-year consensus near $159 million, below the $165 million to $175 million range guided earlier in 2026. Demand is exposed to academic and government research funding, which has been weak and is largely outside the company's control, pressuring instrument sales. Competition is intense: Oxford Nanopore leads the benchtop long-read market Vega is entering, and Illumina dominates the far larger short-read market, so PacBio must keep winning on technology and price. Vega promotional pricing and component costs have weighed on margins, and as a sub-$2 small-cap genomics stock PACB is highly volatile (its 52-week range runs from about $1.07 to $3.44), sensitive to each quarter's placements, guidance revisions, insider sales, and shifts in research budgets.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IP or PACB; figures are approximate and dated (as of November 2026). Verify current data before investing.